Literature DB >> 10620213

Long-term survival in renal transplant recipients with graft function.

A O Ojo1, J A Hanson, R A Wolfe, A B Leichtman, L Y Agodoa, F K Port.   

Abstract

UNLABELLED: Long-term survival in renal transplant recipients with graft function.
BACKGROUND: Death with graft function (DWGF) is a common cause of graft loss. The risks and determinants of DWGF have not been studied in a recent cohort of renal transplant recipients. We performed a population-based survival analysis of U.S. patients with end-stage renal disease (ESRD) transplanted between 1988 and 1997.
METHODS: Registry data were used to evaluate long-term patient survival and cause-specific risks of DWGF in 86,502 adult (>/=18 years) renal transplant recipients.
RESULTS: Out of 18,482 deaths, 38% (N = 7040) were deaths with graft function. This accounts for 42. 5% of all graft loss. Patient survival with graft function was 97, 91, and 86% at 1, 5, and 10 years, respectively. The risk of DWGF decreased by 67% (RR = 0.33, P < 0.001) between 1988 and 1997. The adjusted rate of DWGF was 4.6, 0.8, 2.2, and 1.4 deaths per 1000 person-years for cardiovascular disease, stroke, infections, and malignancy, respectively. The suicide rate was 15.7 versus 9.0 deaths per 100,000 person-years in the general population (P < 0. 001). In multivariate analysis, the following factors were independently and significantly predictive of DWGF: white recipient, age at transplantation, ESRD caused by hypertension or diabetes mellitus, length of pretransplant dialysis, delayed graft function, acute rejection, panel reactive antibody> 30%, African American donor race, age> 45 years, and donor death caused by cerebrovascular disease.
CONCLUSIONS: Patients with graft function have a high long-term survival. Although DWGF is a major cause of graft loss, the risk has declined substantially since 1990. Cardiovascular disease was the predominant reported cause of DWGF. Other causes vary by post-transplant time period. Attention to atherosclerotic risk factors may be the most important challenge to further improve the longevity of patients with successful renal transplants.

Entities:  

Mesh:

Year:  2000        PMID: 10620213     DOI: 10.1046/j.1523-1755.2000.00816.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  137 in total

1.  Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant.

Authors:  Jeffrey J Gaynor; Gaetano Ciancio; Giselle Guerra; Junichiro Sageshima; Lois Hanson; David Roth; Michael J Goldstein; Linda Chen; Warren Kupin; Adela Mattiazzi; Lissett Tueros; Sandra Flores; Luis J Barba; Adrian Lopez; Jose Rivas; Phillip Ruiz; Rodrigo Vianna; George W Burke
Journal:  Diabetologia       Date:  2014-11-01       Impact factor: 10.122

2.  Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States.

Authors:  Jagbir Gill; Marcelo Sampaio; John S Gill; James Dong; Hung-Tien Kuo; Gabriel M Danovitch; Suphamai Bunnapradist
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-21       Impact factor: 8.237

Review 3.  Disparities in kidney transplant outcomes: a review.

Authors:  Elisa J Gordon; Daniela P Ladner; Juan Carlos Caicedo; John Franklin
Journal:  Semin Nephrol       Date:  2010-01       Impact factor: 5.299

4.  Oral supplement of six selective amino acids arrest progression renal failure in uremic patients.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 5.  Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation.

Authors:  Greg Knoll; Sandra Cockfield; Tom Blydt-Hansen; Dana Baran; Bryce Kiberd; David Landsberg; David Rush; Edward Cole
Journal:  CMAJ       Date:  2005-11-08       Impact factor: 8.262

Review 6.  Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale.

Authors:  Moro O Salifu; Fasika Tedla; Serhat Aytug; Amir Hayat; Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

7.  Infectious complications of immune modulatory agents.

Authors:  Ricardo M La Hoz; John W Baddley
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

Review 8.  Combating chronic renal allograft dysfunction : optimal immunosuppressive regimens.

Authors:  Pierre Merville
Journal:  Drugs       Date:  2005       Impact factor: 9.546

9.  More potent lipid-lowering effect by rosuvastatin compared with fluvastatin in everolimus-treated renal transplant recipients.

Authors:  Ida Robertsen; Anders Asberg; Tone Granseth; Nils Tore Vethe; Fatemeh Akhlaghi; Mwlod Ghareeb; Espen Molden; Morten Reier-Nilsen; Hallvard Holdaas; Karsten Midtvedt
Journal:  Transplantation       Date:  2014-06-27       Impact factor: 4.939

Review 10.  Kidney transplantation in the elderly.

Authors:  Edmund Huang; Dorry L Segev; Hamid Rabb
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.